ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

MENLO PARK, Calif.--(BUSINESS WIRE)--Phase 1 trial to evaluate safety and tolerability of a single ascending dose of RCT1100, an inhaled mRNA-based genetic medicine.

Click to view original post